Neopharm Reports Operating Profit of 21.9 Billion KRW Last Year, Down 4.6% Year-on-Year

by Lee Seungjin

Published 08 Feb.2021 16:36(KST)

[Asia Economy Reporter Seungjin Lee] Neopharm announced on the 8th that its consolidated operating profit for last year was tentatively estimated at 21.9 billion KRW, a 4.6% decrease compared to the previous year.

Sales amounted to 81.6 billion KRW, down 1.9% from the previous year. Net profit decreased by 7.2% to 17.8 billion KRW.

Hot Picks Today

Given Grants, Then Says "No Launch" ... Innovative Korean Technology Ultimately Forced Overseas

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
[Breaking] Chairman Park Sookeun: "Possibility of Agreement Instead of Samsung Electronics Labor-Management Mediation Proposal"
"If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
"No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"

Operating profit for the 4th quarter was 6.6 billion KRW, up 16.9% year-on-year, while sales and net profit were 23 billion KRW and 5 billion KRW, respectively.

한글 기사 보기

This content was produced with the assistance of AI translation services.